Circulation levels of acute phase proteins in patients with Takayasu arteritis

Journal of Vascular Surgery

Volumn 51, Issue 3, 2010, Pages 700-706

  Ma, Jun ^a   Luo, Xiaoyun ^a   Wu, Qinghua ^a   Chen, Zhong ^a   Kou, Lei ^a   Wang, Haitao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT COMPONENT C4A; CYCLOPHOSPHAMIDE; FIBRINOGEN; HAPTOGLOBIN; OROSOMUCOID; PREALBUMIN; PREDNISONE; SERUM AMYLOID A; SERUM AMYLOID P;

ACUTE PHASE PROTEIN BLOOD LEVEL; ADULT; AORTA ARCH SYNDROME; ARTICLE; CIRCULATION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCOMPATIBILITY ANTIGENS; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SERUM AMYLOID A PROTEIN; TAKAYASU ARTERITIS; UP-REGULATION; YOUNG ADULT;

EID: 77549087195     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.09.038     Document Type: Article

References (26)

1. Numano F., Okawara M., Inomata H., and Kobayashi Y. Takayasu's arteritis. Lancet 356 (2000) 1023-1025
2. Johnston S.L., Lock R.J., and Gompels M.M. Takayasu arteritis: a review. J Clin Pathol 55 (2002) 481-486
3. Ogino H., Matsuda H., Minatoya K., Sasaki H., Tanaka H., Matsumura Y., et al. Overview of late outcome of medical and surgical treatment for Takayasu arteritis. Circulation 118 (2008) 2738-2747
4. Fields C.E., Bower T.C., Cooper L.T., Hoskin T., Noel A.A., Panneton J.M., et al. Takayasu's arteritis: operative results and influence of disease activity. J Vasc Surg 43 (2006) 64-71
5. Gabay C., and Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
6. Sharma B.K., Jain S., Suri S., and Numano F. Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54 suppl (1996) S141-S147
7. Hoffman G.S. Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol 54 suppl (1996) S99-S102
8. Hata A., Noda M., Moriwaki R., and Numano F. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 54 suppl (1996) S155-S163
9. Arnaud L., Kahn J.E., Girszyn N., Piette A.M., and Bletry O. Takayasu's arteritis: an update on physiopathology. Eur J Intern Med 17 (2006) 241-246
10. Pajari R., Hekali P., and Harjola P.T. Treatment of Takayasu's arteritis: an analysis of 29 operated patients. Thorac Cardiovasc Surg 34 (1986) 176-181
11. Salvarani C., Cantini F., Boiardi L., and Hunder G.G. Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exp Rheumatol 21 6 suppl 32 (2003) S23-S28
12. Oldenburg H.S., Pruitt J.H., Lazarus D.D., Rogy M.A., Chizzonite R., Lowry S.F., et al. Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response. Cytokine 7 (1995) 510-516
13. Kramer F., Torzewski J., Kamenz J., Veit K., Hombach V., Dedio J., et al. Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaB- and C/EBPbeta-dependent autocrine interleukin-6 loop. Mol Immunol 45 (2008) 2678-2689
14. Kim H., and Baumann H. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol 19 (1999) 5326-5338
15. Baumann H., and Gauldie J. Regulation of acute plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 7 (1990) 147-159
16. Tompson D., Milford-Ward A., and Whicher J.T. The value of acute phase measurements in clinical practice. Ann Clin Biochem 29 (1992) 123-131
17. Koenig W., Lowel H., Baumert J., and Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109 (2004) 1349-1353
18. Gomes M.B., Piccirillo L.J., Nogueira V.G., and Matos H.J. Acute-phase proteins among patients with type 1 diabetes. Diabetes Metab 29 (2003) 405-411
19. Hall S., Barr W., Lie J.T., Stanson A.W., Kazmier F.J., and Hunder G.G. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore) 64 (1985) 89-99
20. Park M.C., Lee S.W., Park Y.B., Chung N.S., and Lee S.K. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 34 (2005) 284-292
21. Kerr G.S., Hallahan C.W., Giordano J., Leavitt R.Y., Fauci A.S., Rottem M., et al. Takayasu's arteritis. Ann intern Med 120 (1994) 919-929
22. Lagneau P., Michel J.P., and Vuong P.N. Surgical treatment of Takayasu's disease. Ann Surgery 205 (1987) 157-166
23. Badlato R., Wang J.M., Murphy W.J., Lloyd A.R., Michiel D.F., Bausserman L.L., et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 180 (1994) 203-209
24. Migita K., Kawabe Y., Tominaga M., Origuchi T., Aoyagi T., and Eguchi K. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 78 (1998) 535-539
25. Matsuyama A., Sakai N., Ishigami M., Hiraoka H., Kashine S., Hirata A., et al. Matrix metalloproteinases as a novel disease marker in Takayasu's arteritis. Circulation 108 (2003) 1496-73
26. Kerr G.S. Takayasu's arteritis. Rheum Dis Clin North Am 21 (1995) 1041-1058